Plain-English translation of NCT04460235 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a single injection of works better than the traditional two-vaccine approach (PCV13 followed by PPV23) for protecting lymphoma patients against pneumococcal infection. Adults with lymphoma undergoing chemotherapy have weakened immune systems and are at higher risk for serious pneumococcal disease, but we don't yet know which vaccination strategy works best for them. This study will measure your immune response through blood tests to compare the two approaches.
Chemotherapy for lymphoma damages the immune system, making patients vulnerable to serious infections caused by pneumococcus bacteria. Recent guidelines changed from a two-vaccine schedule to a single newer vaccine, but doctors need to know which approach actually protects lymphoma patients better before recommending one over the other.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of two groups: either receive two pneumococcal vaccine injections spaced 2 months apart, or receive a single injection. You'll have blood drawn at multiple visits over about one year to measure how well your immune system responds to the vaccination. Visits are scheduled at baseline, 4 weeks after the first vaccine, and then several times over the following months to track your immune response.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
France